The FDA approved the use of tezacaftor-ivacaftor (Symdeko, Vertex) for the treatment of pediatric patients aged 6 years and older who have cystic fibrosis (CF) and certain mutations. Last year, the FDA had approved use of this combination in patients aged 12 years and older with those mutations.
“Based on their individual genetic makeup, individuals may respond differently to certain drugs, so it is important to provide a variety of options,” noted Banu Karimi-Shah, MD, the acting